Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer

A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis

(2011) Hyung Soon Park et al.   ONCOLOGY

Preoperative elevation of serum C-reactive protein as an independent prognostic indicator for gastric cancer

(2011) Tadahiro Nozoe et al.   SURGERY TODAY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Systemic Inflammatory Response in Gastric Cancer

(2010) Hiroharu Yamashita et al.   WORLD JOURNAL OF SURGERY

Is Hypoalbuminemia an Independent Prognostic Factor in Patients with Gastric Cancer?

(2010) Andrew B. C. Crumley et al.   WORLD JOURNAL OF SURGERY

Role of systemic inflammatory response in predicting survival in patients with primary operable cancer

(2009) Campbell SD Roxburgh et al.   Future Oncology

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

(2008) Wasaburo Koizumi et al.   LANCET ONCOLOGY

An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer

(2008) Donald C. McMillan   PROCEEDINGS OF THE NUTRITION SOCIETY

Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer

(2007) Andrew B C Crumley et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY